Infliximab Biosimilar CT-P13 Noninferior in Active Crohn ' s Disease Infliximab Biosimilar CT-P13 Noninferior in Active Crohn ' s Disease
The infliximab biosimilar CT-P13 is noninferior to infliximab for treating patients with active Crohn ' s disease, according to a randomized controlled trial.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Gastroenterology News Source Type: news
More News: Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Orthopaedics | Remicade